The US has the capacity to be the global leader in vaccine distributions and production – COVID proves
J. Stephen Morrison and Katherine E. Bliss, 21, (J. Stephen Morrison and Katherine E. Bliss, Senior Vice President and Director, Global Health Policy Center, Katherine is Senior Fellow and Director, Immunizations and Health Systems Resilience, Global Health Policy Center 4-14-2021, Center for Strategic & International Studies, The Time Is Now for U.S. Global Leadership on Covid-19 Vaccines, https://www.csis.org/analysis/time-now-us-global-leadership-covid-19-vaccines, 6-24-2022) SCade
Preface It is in the United States’ strategic interests to ensure that the world mobilizes effectively to end the SARS-CoV-2 pandemic. A proactive U.S. role is essential to secure the gains underway in the United States and ensure Americans’ health, safety, and prosperity into the future. Helping to secure the future of lower- and middle-income countries is also simply the right thing to do, on humanitarian, economic, and security grounds. Today, the United States is quickly approaching a moment of genuine promise, when exceptionally effective vaccines, accelerated distribution at home, and an enlarged American vaccine industrial base open the door for the Biden administration to bring American leadership to urgent global vaccine challenges. The United States’ health, economic, and national security interests argue for seizing this moment, beginning with presidential leadership to explain the stakes to Americans still legitimately worried about the epidemic at home. The United States ignores at its own peril the acute threat posed by viral variants, geopolitical rivals who take advantage of the moment, and deep vaccine inequity around the world. By sharing American vaccine resources starting at the soonest possible moment, the United States can claim ascendancy against these risks. That essential step should be part of a four-part U.S. diplomatic strategy that will: Bring order to the Covid-19 vaccine marketplace; Expand global Covid-19 vaccine supply, including by enhancing manufacturing capacity; Build local Covid-19 vaccine distribution capacity; and Strengthen global demand for Covid-19 vaccines. A Pivot Point of U.S. Confidence The United States should launch a signature global initiative on Covid-19 vaccine supply, delivery, and demand, propelled by high-level U.S. diplomacy and combined with a robust strategy with concrete, quantifiable goals. The Biden administration is on track to reach a pivot point of confidence in managing the domestic epidemic over the course of the summer, and it should seize that opportunity to escalate its international engagement while attending to the ongoing domestic challenges and making the case for U.S. global engagement to the American people. The Biden administration has already taken important steps to support the global vaccination effort but should do more, quickly, to lay the diplomatic and operational groundwork, leveraging the global leadership role of the Office of the President and President Biden’s personal commitment. The administration should signal its intent to begin to scale up the sharing of vaccine doses with lower- and middle-income countries, beginning at the earliest possible moment and accelerating through the fall. It should work with international partners to develop an international coalitional effort to bring greater transparency and accountability to the global vaccine marketplace and to create voluntary incentives for technology transfer to increase regional manufacturing capacity. It should prioritize improving production, quality control, and pricing to ensure equitable access to vaccines. And it should spearhead innovations that will strengthen partner country readiness and increase public trust and confidence in vaccines and vaccine demand. These are fundamentally ethical, economic, and national security matters. Concerted U.S. action internationally will strengthen the protection of Americans at home but also lift the threat posed by the pandemic to the world’s most vulnerable populations, expedite the reopening of the global economy, and enhance U.S. influence in shaping solutions that align with U.S. values and interests. These goals can be advanced while epidemic controls are consolidated at home. And even in the setting of a successful domestic vaccination campaign, failure to adequately address critical vaccine shortages abroad means extended time periods for Covid-19 transmission globally. This longer pandemic window will accentuate human suffering, hamper global economic development, continue to limit international travel for at least the next one to two years, and increase the risk of vaccine-escape variants that can undermine control in the United States and globally. Why act now? The situation at home is changing fundamentally and rapidly. The United States possesses several exceptionally safe and effective vaccines, production is scaling up, and supply stockpiles will soon exceed domestic demand. The rapidly expanding domestic vaccine rollout is laying the groundwork for an exit out of the acute phase of the epidemic at home, at the same time that portions of the $1.9 trillion American Rescue Plan are consolidating the core components of the U.S. domestic response. Confidence is rising steadily that the United States will soon have the suite of tools needed to control the epidemic at home over the summer and stabilize and reopen the economy and society by fall. These promising changes, arriving more quickly than originally anticipated, open the door for increased U.S. engagement globally. At home, leaders will still need to address the risk of a spring surge and the threat of vaccine-escape variants; plan to vaccinate older children by late summer and younger children by late 2021 and into 2022; address the possible manufacturing and distribution of booster shots and recurrent vaccines; continue to urge masking and social distancing measures and also find and stop clusters; and answer the questions of Americans who have concerns about vaccine safety or refuse to accept them. The race will continue to resolve scientific unknowns (e.g., how effectively vaccines stop infectious transmission by variants, including those that have not yet emerged; and how long immunity lasts). But with the rapid deepening of U.S. capacities and the expansion of vaccine coverage, the United States is in a much better position to manage these challenges—and engage more intensively outside its borders.